All News

Check out a recap of important pharmacy news you might have missed this week, dispensed in small doses.

Check out these important FDA updates from the month of July 2024.

Researchers aimed to address the associations between prenatal cannabis use and maternal health outcomes over a 9-year period.

The American College of Allergy, Asthma, and Immunology (ACAAI) recently released its 5 tips to help children and their parents stay educated on asthma peak month.

Galderma said the FDA has accepted the company’s Biologics License Application for the therapy based on data from the trials.

In the final part of his conversation on Over the Counter, Mayank Amin, PharmD, RPh, MBA, reflects on 5-years worth of learnings at Skippack Pharmacy and offers candid perspectives on the future of community pharmacy.

In part 3 of his conversation with Drug Topics on Over the Counter, Mayank Amin, PharmD, RPh, MBA, continues his inspiring story of reopening Skippack Pharmacy and details the beginnings of The Superman Pharmacist.

Check out these featured Drug Topics interviews from July 2024.

Full efficacy and safety results for the phase 3 PURPOSE 1 trial were announced by Gilead at AIDS 2024.

In a House Committee on Oversight and Accountability hearing, Democrats and Republicans took a bipartisan stance to question the role major PBMs play regarding rising drug costs in the US.

PASO DOBLE is the largest head-to-head, phase 4 randomized clinical trial comparing DTG/3TC and BIC/FTC/TAF in patients with HIV.

From 2021 to 2022, the prevalence of adults with diabetes who used cannabis increased by 33.7%.

A survey conducted by Surescripts, a health care solutions company, explored the attitudes of pharmacists and prescribers towards ongoing issues and challenges currently facing the industry.

In part 2 of his interview with Drug Topics featured on Over the Counter, Mayank Amin, PharmD, RPh, MBA, discusses how he redefined the role of a pharmacy at Skippack Pharmacy.

In part 1 of a recent conversation on Over the Counter, Mayank Amin, PharmD, RPh, MBA, shared his journey from pharmacy school to pharmacy ownership.

MK-1654 (clesrovimab) met its primary efficacy endpoint of incidence of patients with RSV-associated medically attended lower respiratory infections (MALRI) through Day 150.

Industry experts explored the increase in US prescription drug spending and how state spending targets come into play regarding patients’ rising out-of-pocket costs.

Check out important updates from the FDA from over the past week.

The most common adverse events in patients using oral corticosteroids for more than 90 days included fracture, hyperlipidemia, myocardial infarction, and avascular necrosis.

Researchers aimed to determine the risks and benefits of prescription drug advertising released in tandem with disease awareness programming.

The approval of eculizumab-aagh offers more treatment options for patients with rare diseases PNH and aHUS.

Steve Postal, JD, Director of Policy and Regulatory Affairs at the National Community Pharmacists Association (NCPA), sat down with Drug Topics to discuss Pharmacy Benefit Managers.

In case you missed it, this week we had news about cybersecurity breaches at Rite Aid, advancements in chronic hand eczema treatment, the Superman Pharmacist, and more.

Check out this recap of articles published on our sister sites during the past week.

Check out a recap of important pharmacy news you might have missed this week, dispensed in small doses.

Delgocitinib cream from LEO Pharmaceuticals showed superior efficacy compared to cream vehicle and was well tolerated over 16 weeks.

The collaboration between Surescripts and DAW Systems leverages Surescripts’ established e-prescribing network, which last year processed 2.5 billion prescriptions from 1.29 million prescribers across the US.

Steve Postal, JD, Director of Policy and Regulatory Affairs at the National Community Pharmacists Association (NCPA), discussed pharmacy benefit managers and vehicles necessary to induce reform.

The initiative by Boehringer and GoodRx has the potential to accelerate the therapeutic timeline for patients treated with the biosimilar.

House Bill (HB) 1993 seeks to increase PBM transparency and accountability in an effort to combat the rising cost of prescription drugs.